Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PLSE

Pulse Biosciences Inc

Jul 26 • 04:00PM ET

17.07

Dollar change -0.64
Percentage change -3.61	%

Healthcare • Medical Instruments & Supplies • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: IWM VTI IWO VXF IWC VTWO ISMD VTWG ITOT RSSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.82	Insider Own	80.13%	Shs Outstand	55.14M	Perf Week	6.95%
Market Cap	1.05B	Forward P/E	-	EPS next Y	-	Insider Trans	0.02%	Shs Float	12.17M	Perf Month	71.21%
Income	-42.55M	PEG	-	EPS next Q	-	Inst Own	7.73%	Short Float	23.00%	Perf Quarter	155.16%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-14.02%	Short Ratio	10.10	Perf Half Y	102.25%
Book/sh	0.66	P/B	25.98	EPS next Y	-	ROA	-71.28%	Short Interest	2.80M	Perf Year	140.42%
Cash/sh	0.57	P/C	29.97	EPS next 5Y	-	ROE	-332.14%	52W Range	3.78 - 20.44	Perf YTD	39.46%
Dividend Est.	-	P/FCF	-	EPS past 5Y	16.76%	ROI	-96.51%	52W High	-16.48%	Beta	1.68
Dividend TTM	-	Quick Ratio	7.06	Sales past 5Y	-30.13%	Gross Margin	-	52W Low	351.59%	ATR (14)	1.74
Dividend Ex-Date	-	Current Ratio	7.06	EPS Y/Y TTM	43.33%	Oper. Margin	0.00%	RSI (14)	58.75	Volatility	11.29% 12.20%
Employees	56	Debt/Eq	0.25	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	3.00	Target Price	5.00
Option/Short	Yes / Yes	LT Debt/Eq	0.21	EPS Q/Q	29.91%	Payout	-	Rel Volume	0.85	Prev Close	17.71
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	May 07 AMC	Avg Volume	277.13K	Price	17.07
SMA20	11.67%	SMA50	31.86%	SMA200	84.20%	Trades		Volume	235,494	Change	-3.61%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-27-21	Initiated	Stephens	Overweight	$28
Mar-11-21	Initiated	Maxim Group	Buy	$40
Jan-26-21	Reiterated	H.C. Wainwright	Buy	$16 → $40
May-12-20	Upgrade	H.C. Wainwright	Neutral → Buy	$6 → $16
Feb-14-20	Downgrade	H.C. Wainwright	Buy → Neutral	$26 → $6
Feb-25-19	Initiated	H.C. Wainwright	Buy	$27

Jul-09-24 07:27AM	Pulse drops 510(k) plan for PFA device after FDA requests clinical data (MedTech Dive)
06:53AM	Pulse Biosciences receives breakthrough device status for CellFX system (Medical Device Network)
Jul-08-24 08:00AM	Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation (Business Wire) +28.71%
Jul-03-24 02:44PM	Pulse Biosciences, Inc. Announces the Closing of its Rights Offering (Business Wire)
Jun-28-24 08:00AM	Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering (Business Wire)
08:00AM	Loading…
Jun-04-24 08:00AM	Pulse Biosciences, Inc. Announces Commencement of Rights Offering (Business Wire)
May-20-24 05:39PM	Pulse Biosciences Moves New Record Date for Rights Offering (MT Newswires) +9.86% +13.40%
04:05PM	Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000 (Business Wire)
May-17-24 06:41AM	Pulse Biosciences names new CEO, reassigns former leader (MedTech Dive)
May-16-24 08:00AM	Pulse Biosciences CellFX Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting (Business Wire) +8.68%
May-14-24 05:17PM	Pulse Biosciences Appoints Burke Barrett as President, CEO (MT Newswires) +7.55% -5.59%
04:05PM	Pulse Biosciences Enhances Executive Leadership Team (Business Wire)
May-13-24 09:02AM	Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 08:00AM	Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System (Business Wire)
May-08-24 06:06AM	Q1 2024 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -9.21%
03:56AM	Loading…
03:56AM	Pulse Biosciences Inc (PLSE) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-07-24 09:56PM	PLSE Stock Earnings: Pulse Biosciences Reported Results for Q1 2024 (InvestorPlace)
05:45PM	Pulse Biosciences Reports Q1 2024 Financial Results Amidst Strategic Business Developments (GuruFocus.com)
04:05PM	Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results (Business Wire)
May-02-24 08:00AM	Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000 (Business Wire) +5.92%
Apr-28-24 11:59AM	5 ChatGPT Penny Stock Picks Right Now (Insider Monkey)
Apr-24-24 04:05PM	Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024 (Business Wire)
Apr-01-24 04:19PM	Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2023 Earnings Call Transcript (Insider Monkey) -8.27%
Mar-29-24 06:30AM	Q4 2023 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-28-24 10:53PM	PLSE Stock Earnings: Pulse Biosciences Reported Results for Q4 2023 (InvestorPlace) -8.27%
05:51PM	Pulse Biosciences Inc (PLSE) Reports Increased GAAP Costs and Narrowed Net Loss in 2023 (GuruFocus.com)
04:12PM	Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results (Business Wire)
04:10PM	Pulse Biosciences Announces Plans to Initiate a Rights Offering (Business Wire)
Mar-14-24 04:05PM	Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024 (Business Wire)
Mar-08-24 01:17PM	Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX nsPFA Percutaneous Electrode System (Business Wire)
08:00AM	Loading…
Feb-14-24 08:00AM	Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX nsPFA 360 Cardiac Catheter First-in-Human Feasibility Study (Business Wire) +12.56%
Jan-31-24 08:00AM	Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium (Business Wire)
Jan-02-24 08:00AM	Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp (Business Wire) -9.97%
Dec-20-23 08:00AM	Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation (nsPFA) Cardiac Catheter (Business Wire) -7.11%
Nov-21-23 08:00AM	Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode (Business Wire) +5.59%
Nov-15-23 04:05PM	Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference (Business Wire) +9.62%
Nov-14-23 12:52PM	Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2023 Earnings Call Transcript (Insider Monkey) +7.58%
02:15AM	Q3 2023 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-13-23 11:13AM	Pulse Biosciences Inc (PLSE) Reports Decrease in Q3 Losses and Advances in Cardiac Device ... (GuruFocus.com)
08:00AM	Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results (Business Wire)
Nov-10-23 04:56PM	UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call (Business Wire) +11.57%
Oct-30-23 04:05PM	Pulse Biosciences Schedules Third Quarter 2023 Financial Results Conference Call for November 13, 2023 (Business Wire) +5.76%
Oct-24-23 08:00AM	Pulse Biosciences Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery (Business Wire)
Oct-02-23 08:00AM	Pulse Biosciences Announces Collaboration with CardioNXT for nsPFA First-in-Human Atrial Fibrillation Study (Business Wire)
Sep-29-23 08:00AM	Pulse Biosciences Nanosecond Pulsed Field Ablation (nsPFA) Circumferential Catheter System to be Featured in a Presentation at the Global EP Summit (Business Wire) -7.57%
Sep-27-23 08:00AM	Pulse Biosciences First Study in a Surgical Application of Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Two Poster Presentations at the American Thyroid Association Annual Meeting (Business Wire)
Sep-07-23 04:05PM	Pulse Biosciences to Present at Gilmartin Group Emerging Growth Showcase (Business Wire)
Aug-24-23 04:05PM	Pulse Biosciences Clarifies Details of Recent S-3 Filing (Business Wire) -8.95%
Aug-17-23 09:31AM	15 Best-Performing Stocks in the Last 12 Months (Insider Monkey)
Aug-11-23 06:28AM	Q2 2023 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) +5.56%
Aug-10-23 04:05PM	Pulse Biosciences Reports Business Updates and Second Quarter 2023 Financial Results (Business Wire) -5.66%
Jul-30-23 09:35AM	Pulse Biosciences, Inc. (NASDAQ:PLSE) insiders have had a fantastic week as stock increased 31%, and they haven't stopped buying (Simply Wall St.)
Jul-27-23 04:05PM	Pulse Biosciences Schedules Second Quarter 2023 Financial Results Conference Call for August 10, 2023 (Business Wire) +25.61%
May-22-23 09:30AM	11 Stocks with Heavy Insider Buying in 2023 (Insider Monkey) -7.94%
May-18-23 07:00AM	Pulse Biosciences Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Several Presentations at The Heart Rhythm 2023 Annual Meeting (Business Wire) -5.73%
May-16-23 12:01PM	Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-12-23 07:43AM	Q1 2023 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) +6.31%
May-11-23 04:05PM	Pulse Biosciences Reports Business Updates and First Quarter 2023 Financial Results (Business Wire) -8.31%
May-10-23 09:29AM	Pulse Biosciences, Inc. Announces Planned Redemption of Warrants (Business Wire)
May-03-23 08:00AM	Pulse Biosciences, Inc. Appoints Dr. Gan Dunnington as Chief Medical Officer (Business Wire) +19.19%
May-01-23 08:00AM	Pulse Biosciences Announces $65 Million Private Placement (Business Wire) +5.75%
Apr-27-23 04:05PM	Pulse Biosciences Schedules First Quarter 2023 Financial Results Conference Call for May 11, 2023 (Business Wire) +8.97%
Apr-20-23 06:04AM	As Pulse Biosciences, Inc. (NASDAQ:PLSE) hits US$217m market cap, insiders may be dismayed about not purchasing higher quantities (Simply Wall St.)
Apr-05-23 07:46PM	Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-30-23 04:05PM	Pulse Biosciences Reports Fourth Quarter & Full Year 2022 Financial Results (Business Wire) +35.48%
Mar-10-23 08:30AM	Even after rising 18% this past week, Pulse Biosciences (NASDAQ:PLSE) shareholders are still down 79% over the past five years (Simply Wall St.) +8.78%
Mar-02-23 04:05PM	Pulse Biosciences Schedules Fourth Quarter & Full Year 2022 Financial Results Conference Call for March 30, 2023 (Business Wire)
Feb-02-23 08:00AM	Pulse Biosciences Announces Its Novel Nanosecond Pulsed Field Ablation System Will Be Highlighted at the 2023 AF Symposium (Business Wire)
Dec-10-22 07:24AM	Pulse Biosciences, Inc. (NASDAQ:PLSE) insiders have recently purchased stock and their bets paid off last week as company hit US$108m market cap (Simply Wall St.)
Nov-10-22 04:05PM	Pulse Biosciences Reports Third Quarter 2022 Financial Results (Business Wire) +13.04%
Oct-27-22 04:05PM	Pulse Biosciences Schedules Third Quarter 2022 Financial Results Conference Call for November 10, 2022 (Business Wire) -5.02%
Oct-14-22 06:17AM	Insider Buying: The Pulse Biosciences, Inc. (NASDAQ:PLSE) Chief Strategy Officer & Director Just Bought 70% More Shares (Simply Wall St.) -5.83%
Oct-06-22 08:00AM	Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions (Business Wire) -9.81%
Oct-01-22 08:50AM	Pulse Biosciences (NASDAQ:PLSE) adds US$29m to market cap in the past 7 days, though investors from a year ago are still down 89% (Simply Wall St.)
Sep-26-22 10:00AM	Pulse Biosciences Lead Therapeutic System Scores FDA Approval For Sebaceous Hyperplasia (Benzinga) +18.30%
08:00AM	Pulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia (Business Wire)
Sep-21-22 10:03AM	Pulse Biosciences Shifts Core Technology Focus, Reduces Dermatologic Footprint (Benzinga) +7.19%
Sep-20-22 04:26PM	Pulse Biosciences Announces Strategic Change of Focus in Support of Significant Additional Opportunities for medicinal related Nano-Pulse Stimulation (Business Wire)
Aug-10-22 05:25PM	Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +6.88%
04:05PM	Pulse Biosciences Reports Second Quarter 2022 Financial Results (Business Wire)
Aug-04-22 08:00AM	Pulse Biosciences Receives FDA 510(k) Clearance of Expanded Energy Settings for use with the CellFX® System (Business Wire)
Jul-27-22 04:05PM	Pulse Biosciences Schedules Second Quarter 2022 Financial Results Conference Call for August 10, 2022 (Business Wire)
Jun-16-22 04:15PM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.37%
Jun-09-22 04:43PM	Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering (Business Wire) -13.18%
Jun-03-22 08:00AM	Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering (Business Wire)
May-19-22 08:00AM	Pulse Biosciences, Inc. Announces Changes to its Rights Offering (Business Wire)
May-13-22 01:44PM	Stock rebound uncertain for U.S. biotechs as risks multiply for investors (American City Business Journals) +14.86%
May-11-22 06:05PM	Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -17.17% -23.32%
04:05PM	Pulse Biosciences Reports First Quarter 2022 Financial Results (Business Wire)
May-04-22 08:00AM	Pulse Biosciences, Inc. Announces Commencement of Rights Offering (Business Wire)
Apr-28-22 08:00AM	Pulse Biosciences Schedules First Quarter 2022 Financial Results Conference Call for May 11, 2022 (Business Wire)
Apr-26-22 08:00AM	Pulse Biosciences to Present New Data on Nano-Pulse Stimulation Procedure for Sebaceous Hyperplasia and for Focal Epithelial Hyperplasia at 2022 American Society of Laser Medicine and Surgery Annual Conference (Business Wire) -8.20%
Apr-14-22 04:05PM	Pulse Biosciences, Inc. Announces Rights Offering (Business Wire) -6.72% -9.22%
Mar-31-22 05:25PM	Pulse Biosciences, Inc (PLSE) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -26.95%
04:05PM	Pulse Biosciences Reports Fourth Quarter & Full Year 2021 Financial Results (Business Wire)
Mar-21-22 04:05PM	Pulse Biosciences Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call for March 31, 2022 (Business Wire) -9.89%
Mar-17-22 06:57AM	A Pulse Biosciences, Inc. (NASDAQ:PLSE) insider increased their holdings by 25% last year (Simply Wall St.) +8.56%
Feb-15-22 08:00AM	Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer (Business Wire)
Feb-08-22 12:37PM	What Is Happening With Pulse Biosciences Stock Today? (Benzinga) -34.44%
08:45AM	Pulse Biosciences Provides an Update on Recent FDA 510(k) Submission (Business Wire)

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Barrett Burke Thomas	President and CEO	May 20 '24	Buy	8.56	10,000	85,600	10,000	May 22 02:07 PM
DUGGAN ROBERT W	Director	Dec 12 '23	Buy	9.15	17,999	164,691	36,984,179	Dec 14 07:37 PM
DUGGAN ROBERT W	Director	Dec 11 '23	Buy	9.36	90,118	843,504	36,966,180	Dec 13 06:03 PM
DUGGAN ROBERT W	Director	Dec 08 '23	Buy	9.54	116,656	1,112,898	36,876,062	Dec 12 07:28 PM
DUGGAN ROBERT W	Director	Dec 07 '23	Buy	9.19	74,852	687,890	36,759,406	Dec 11 08:13 PM
DUGGAN ROBERT W	Director	Dec 06 '23	Option Exercise	5.95	9,933	59,101	36,601,741	Dec 08 07:38 PM
DUGGAN ROBERT W	Director	Dec 06 '23	Buy	9.06	82,813	750,286	36,684,554	Dec 08 07:38 PM
DUGGAN ROBERT W	Director	Dec 05 '23	Buy	9.34	66,021	616,636	351,565	Dec 07 08:34 PM
DUGGAN ROBERT W	Director	Dec 04 '23	Option Exercise	10.66	40,347	430,099	36,591,808	Dec 06 07:54 PM
DUGGAN ROBERT W	Director	Dec 04 '23	Buy	10.38	27,000	280,260	285,544	Dec 06 07:54 PM
DUGGAN ROBERT W	Director	Dec 01 '23	Buy	9.07	45,600	413,592	258,544	Dec 05 08:31 PM
DUGGAN ROBERT W	Director	Nov 30 '23	Buy	9.06	152,944	1,385,673	212,944	Dec 04 07:37 PM
DUGGAN ROBERT W	Director	Nov 29 '23	Option Exercise	5.95	1,667	9,919	36,392,861	Dec 01 07:36 PM
DUGGAN ROBERT W	Director	Nov 29 '23	Buy	9.44	158,600	1,497,184	36,551,461	Dec 01 07:36 PM
DUGGAN ROBERT W	Director	Nov 29 '23	Buy	9.21	60,000	552,600	60,000	Dec 01 07:36 PM
DUGGAN ROBERT W	Director	Nov 28 '23	Buy	8.98	124,397	1,117,085	36,391,194	Nov 30 07:25 PM
DUGGAN ROBERT W	Director	Nov 17 '23	Buy	6.10	20,241	123,470	36,266,797	Nov 20 08:56 PM
Danahy Kevin Patrick	Chief Executive Officer	Nov 16 '23	Buy	6.52	5,393	35,156	35,887	Nov 17 09:11 AM
Levinson Mitchell E.	Chief Strategy Officer	Nov 15 '23	Buy	5.91	13,539	80,058	9,135	Nov 17 09:10 AM
Levinson Mitchell E.	Chief Strategy Officer	Nov 15 '23	Buy	5.87	4,261	25,033	73,027	Nov 17 09:10 AM
Zanganeh Mahkam	Director	Nov 13 '23	Option Exercise	2.14	76,075	162,800	604,911	Nov 15 05:37 PM
DUGGAN ROBERT W	Director	Nov 07 '23	Option Exercise	5.95	13,265	78,927	36,246,556	Nov 09 06:32 PM
DUGGAN ROBERT W	Director	Aug 25 '23	Option Exercise	5.95	1,667	9,919	36,233,291	Aug 28 08:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PLSE

Pulse Biosciences Inc

Upgrade your FINVIZ experience